云南白药（000538）：业绩稳健增长，药品事业群表现亮眼

Investment Rating - The investment rating for Yunnan Baiyao is "Buy-A" with a target price of 64.49 yuan for the next six months, which corresponds to a dynamic price-to-earnings ratio of 22 times for 2025 [8][11]. Core Insights - The company reported a steady growth in performance for 2024, achieving a revenue of 40.033 billion yuan, a year-on-year increase of 2.36%, and a net profit of 4.749 billion yuan, up 16.02% year-on-year [1][11]. - The pharmaceutical business segment showed remarkable performance, with a revenue of 6.924 billion yuan, reflecting an 11.8% year-on-year growth, and ten products exceeding 100 million yuan in sales [2][3]. - The health products segment generated a revenue of 6.526 billion yuan, a 1.6% increase year-on-year, with the oral care product line maintaining the top market share in China [3][9]. Summary by Sections Financial Performance - In Q4 2024, the company achieved a revenue of 10.118 billion yuan, a 7.38% year-on-year increase, and a net profit of 0.423 billion yuan, with a non-recurring net profit of 0.258 billion yuan, marking a turnaround from losses [1]. - The gross margin improved to 27.90%, up 1.39 percentage points year-on-year, and the net profit margin reached 11.91%, an increase of 1.37 percentage points [1]. Business Segments - Pharmaceutical Segment: The main business revenue was 6.924 billion yuan, with significant growth in core products such as Yunnan Baiyao aerosol, which surpassed 2.1 billion yuan in sales, growing over 26% year-on-year [2]. - Health Products Segment: Revenue reached 6.526 billion yuan, with a notable 30.3% increase in sales for the anti-hair loss product line [3]. - Traditional Chinese Medicine Resources Segment: Generated 1.751 billion yuan in revenue, with a 3.13% year-on-year growth, while maintaining stable supply and pricing for strategic products [3]. - Provincial Pharmaceutical Company: Achieved a revenue of 24.607 billion yuan, a 0.48% increase year-on-year, with significant growth in non-pharmaceutical business areas [9]. Innovation and Development - The company is focusing on innovation with ongoing projects in short, medium, and long-term development, including secondary innovation of major traditional Chinese medicine products and new drug development [10][11]. - The projected revenue growth rates for 2025 to 2027 are estimated at 4.7%, 4.5%, and 4.5%, respectively, with net profit growth rates of 10.1%, 9.5%, and 8.7% [11].